<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109208</url>
  </required_header>
  <id_info>
    <org_study_id>21-001713</org_study_id>
    <nct_id>NCT05109208</nct_id>
  </id_info>
  <brief_title>The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction</brief_title>
  <official_title>Ultrasound Vibroelastography in Post-Prostatectomy Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine whether there is additional utility to using&#xD;
      vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue&#xD;
      fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile&#xD;
      function (recovery) after prostate cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Viscoelasticity</measure>
    <time_frame>Baseline, 3 months, 6 months and 9 months post-prostatectomy</time_frame>
    <description>As measured by Ultrasound Vibroelastography (UVE)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ultrasound viscoelastography (UVE) in radical proctectomy recovery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergoing radical prostatectomy for prostate cancer disease as standard of care will have a ultrasound vibroelastography performed before surgery, 3 months, 6 months and 9 months post-prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ulrasound Vibroelastography (UVE)</intervention_name>
    <description>Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).</description>
    <arm_group_label>Ultrasound viscoelastography (UVE) in radical proctectomy recovery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include:&#xD;
&#xD;
          -  Age &gt; 40 years&#xD;
&#xD;
          -  Clinically localized prostate cancer (American Urological Association Grade Groups&#xD;
             1-2; cT1c or cT2a-b; PSA &lt; 10) without clinic or imaging evidence of localized&#xD;
             extra-prostatic or metastatic disease (i.e. AUA low and favorable intermediate risk&#xD;
             prostate cancer)&#xD;
&#xD;
          -  International Index of Erectile Function (IIEF) of â‰¥ 21 points at baseline (no or mild&#xD;
             erectile dysfunction)&#xD;
&#xD;
          -  Patient-expressed interest in consultation for sexual function (erectile function)&#xD;
             preservation/ optimization&#xD;
&#xD;
          -  Planned bilateral nerves-paring prostatectomy&#xD;
&#xD;
        Exclusion criteria include:&#xD;
&#xD;
          -  Moderate or severe ED based in IIEF criteria (score &lt; 21)&#xD;
&#xD;
          -  History of prior pelvic or penile surgery&#xD;
&#xD;
          -  Current or prior androgen deprivation therapy&#xD;
&#xD;
          -  Planned non-nerve sparing prostatectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Ziegelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Ziegelmann</last_name>
      <phone>507-266-3982</phone>
      <email>Ziegelmann.mathew@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew (Matt) J. Ziegelmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Radical Prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

